Contrast Media

A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for magnetic resonance imaging (MRI) has not identified adverse health affects from gadolinium retained in the brain. The FDA released a drug safety communication regarding all...

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new recommendations on procedures employing gadolinium-based contrast agents, in which the committee recommended suspension of marketing authorization for four agents.

The most prevalent method for obtaining images of clogged coronary vessels is coronary angiography. For some patients, however, the contrast agents used in this process can cause health problems. A team at the Technical University of Munich (TUM) has now demonstrated that the required quantity...

Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The update removes the contraindication statement related to use in patients with a known or suspected cardiac...

Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be associated with chronic kidney disease, dialysis, kidney transplant or acute kidney injury, despite long-held fears to the contrary. The results of the largest controlled study of...